Dr. Jenny Rooke is the Founder and serves as Managing Partner & Managing Director at Genoa Ventures. She serves as a Board Member of BrightSpec, Meiogenix and InterVenn BioSciences. She is an early-stage venture capital investor. She is the Founder and serves as a Managing Director at 5 Prime Ventures. She served as Board Member at Adarza BioSystems. She also served as a Venture Partner at F-Prime Capital Partners (healthcare) and Anterra Capital (agriculture). She serves as Board Member at Stemson Therapeutics. She brings a combination of strategy, operating, and investing experience to her work with early-stage life science companies, specializing in research tools, diagnostics, and synthetic biology. Her investing experience includes roles in the Bill & Melinda Gates Foundation's Global Health Discovery group, and at F-Prime Capital, where she has served her Kauffman Fellowship. Dr. Rooke held multiple executive positions at U.S. Genomics, a venture-backed biotech start-up advancing single-molecule detection technologies for diagnostics, biodefense, and research. Previously, Dr. Rooke was a management consultant with McKinsey & Co., where she advised leading pharmaceutical and biotech companies on business strategy. Dr. Rooke earned her Ph.D. in genetics from Yale University and her B.S. in physics from Georgia Tech. She serves as Board Member at Intabio and Venn.